

# Victor Goncalves

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2324684/publications.pdf>

Version: 2024-02-01

30  
papers

938  
citations

430442

18  
h-index

476904

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1591  
citing authors

#	ARTICLE	IF	CITATIONS
1	Site-Specific, Platform-Based Conjugation Strategy for the Synthesis of Dual-Labeled Immunoconjugates for Bimodal PET/NIRF Imaging of HER2-Positive Tumors. <i>Bioconjugate Chemistry</i> , 2022, 33, 530-540.	1.8	10
2	Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tumors. <i>Cancers</i> , 2021, 13, 428.	1.7	18
3	Positron Emission Tomography Imaging of Neurotensin Receptor-Positive Tumors with <sup>68</sup> Ga-Labeled Antagonists: The Chelate Makes the Difference Again. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8564-8578.	2.9	8
4	Additional information on "Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for <sup>89</sup> Zr-immunoPET". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 505-506.	3.3	2
5	Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2426-2433.	2.9	23
6	Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging. <i>Nuclear Medicine and Biology</i> , 2020, 82-83, 49-56.	0.3	4
7	Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for <sup>89</sup> Zr-immunoPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1966-1977.	3.3	54
8	Modular Assembly of Multimodal Imaging Agents through an Inverse Electron Demand Diels-Alder Reaction. <i>Bioconjugate Chemistry</i> , 2019, 30, 888-897.	1.8	21
9	Site-specific near-infrared fluorescent labelling of proteins on cysteine residues with <i>meso</i> -chloro-substituted heptamethine cyanine dyes. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 8831-8836.	1.5	31
10	Site-Specific Dual Labeling of Proteins on Cysteine Residues with Chlorotetrazines. <i>Angewandte Chemie</i> , 2018, 130, 10806-10810.	1.6	9
11	Site-Specific Dual Labeling of Proteins on Cysteine Residues with Chlorotetrazines. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 10646-10650.	7.2	47
12	<sup>89</sup> Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art <sup>89</sup> Zr Radiochemistry. <i>Bioconjugate Chemistry</i> , 2017, 28, 2211-2223.	1.8	146
13	Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. <i>MedChemComm</i> , 2017, 8, 191-197.	3.5	14
14	Direct subphthalocyanine conjugation to bombesin vs. indirect conjugation to its lipidic nanocarrier. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 4511-4518.	1.5	14
15	BODIPY: A Highly Versatile Platform for the Design of Bimodal Imaging Probes. <i>Chemistry - A European Journal</i> , 2015, 21, 13091-13099.	1.7	25
16	MA-NOTMP: A Triazacyclononane Trimethylphosphinate Based Bifunctional Chelator for Gallium Radiolabelling of Biomolecules. <i>ChemMedChem</i> , 2015, 10, 1475-1479.	1.6	10
17	(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. <i>PLoS ONE</i> , 2015, 10, e0145755.	1.1	46
18	Towards the elaboration of new gold-based optical theranostics. <i>Dalton Transactions</i> , 2015, 44, 4874-4883.	1.6	32

#	ARTICLE	IF	CITATIONS
19	DMAPâ€BODIPY Alkynes: A Convenient Tool for Labeling Biomolecules for Bimodal PETâ€“Optical Imaging. Chemistry - A European Journal, 2014, 20, 12933-12944.	1.7	25
20	Structure-Based Design of Potent and Selective <i>Leishmania</i> <i>N</i> -Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8664-8670.	2.9	56
21	Discovery of Plasmodium vivax <i>N</i> -Myristoyltransferase Inhibitors: Screening, Synthesis, and Structural Characterization of their Binding Mode. Journal of Medicinal Chemistry, 2012, 55, 3578-3582.	2.9	65
22	A fluorescence-based assay for N-myristoyltransferase activity. Analytical Biochemistry, 2012, 421, 342-344.	1.1	69
23	Targeting the Proangiogenic VEGF-VEGFR Protein-Protein Interface with Drug-like Compounds by In Silico and In Vitro Screening. Chemistry and Biology, 2011, 18, 1631-1639.	6.2	38
24	Biochemical and Structural Analysis of the Binding Determinants of a Vascular Endothelial Growth Factor Receptor Peptidic Antagonist. Journal of Medicinal Chemistry, 2010, 53, 4428-4440.	2.9	31
25	Total chemical synthesis of the D2 domain of human VEGF receptor 1. Journal of Peptide Science, 2009, 15, 417-422.	0.8	10
26	Cyclic peptides as VEGF receptor antagonist. Advances in Experimental Medicine and Biology, 2009, 611, 479-480.	0.8	0
27	Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors. Journal of Peptide Science, 2008, 14, 767-772.	0.8	12
28	Rational Design, Structure, and Biological Evaluation of Cyclic Peptides Mimicking the Vascular Endothelial Growth Factor. Journal of Medicinal Chemistry, 2007, 50, 5135-5146.	2.9	33
29	On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azideâ€“alkyne cycloaddition. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5590-5594.	1.0	41
30	Development of a chemiluminescent screening assay for detection of vascular endothelial growth factor receptor 1 ligands. Analytical Biochemistry, 2007, 366, 108-110.	1.1	42